Pagina 1 a partire dal 19 risultati
BACKGROUND OF THE INVENTION
The present invention is drawn to somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use.
Dopamine is a catecholamine neurotransmitter that has been implicated in the pathogenesis of both Parkinson disease and schizophrenia. Dopamine and
BACKGROUND OF THE INVENTION
The present invention is drawn to somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use.
Dopamine is a catecholamine neurotransmitter that has been implicated in the pathogenesis of both Parkinson disease and schizophrenia. Dopamine and
FIELD OF THE INVENTION
The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other
FIELD OF THE INVENTION
The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other
FIELD OF THE INVENTION
The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/EP2015/058380 filed 17 Apr. 2015, which claims priority to European Patent Application No. 14165053.1 filed 17 Apr. 2014. The entire contents of
FIELD OF THE INVENTION
The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and saccharide enzyme activity. The invention is further directed to methods and compositions for treating tumors having high tyrosinase
FIELD OF THE INVENTION
The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and .beta.-glucuronidase activity. The invention is further directed to methods and compositions for treating tumors having high
FIELD OF THE DISCLOSURE
The disclosure relates to methods and compositions for the treatment of cancer and particularly to methods and compositions for the treatment of cancer with a dopamine receptor antagonist and chemotherapeutic agent.
BACKGROUND OF THE DISCLOSURE
Increasing evidence suggests
FIELD OF THE DISCLOSURE
The disclosure relates to methods and compositions for the treatment of cancer and particularly to methods and compositions for the treatment of cancer with a dopamine receptor antagonist and chemotherapeutic agent.
BACKGROUND OF THE DISCLOSURE
Increasing evidence suggests
BACKGROUND OF THE INVENTION
Cancer is a disease that begins with mutation of critical genes: oncogenes and tumor suppressor genes. Mutation of critical genes allows for a cancer cell to evolve and ultimately results in pathogenic replication (a loss of normal regulatory control leading to excessive
FIELD OF THE DISCLOSURE
The disclosure relates to methods for the prognosis or treatment of cancer and screening methods and particularly to methods for the prognosis or treatment of cancer that target dopamine receptors and screening methods for the identification and validation of agents that
BACKGROUND OF THE INVENTION
ONC201 (7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo [1,2-a]pyrido [3,4-e]pyrimidin-5(1H)-one) is the founding member of a class of anti-cancer compounds called imipridones that is in Phase II clinical trials in multiple advanced cancers. Since the discovery
BACKGROUND OF THE INVENTION
ONC201 (7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo [1,2-a]pyrido [3,4-e]pyrimidin-5(1H)-one) is the founding member of a class of anti-cancer compounds called imipridones that is in Phase II clinical trials in multiple advanced cancers. Since the discovery
FIELD OF THE INVENTION
The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present